Novel role for epalrestat: protecting against NLRP3 inflammasome-driven NASH by targeting aldose reductase.

ABSTRACT:

Background

Nonalcoholic steatohepatitis (NASH) is a progressive and inflammatory subtype of nonalcoholic fatty liver disease (NAFLD) characterized by hepatocellular injury, inflammation, and fibrosis in various stages. More than 20% of patients with NASH will progress to cirrhosis. Currently, there is a lack of clinically effective drugs for treating NASH, as improving liver histology in NASH is difficult to achieve and maintain through weight loss alone. Hence, the present study aimed to investigate potential therapeutic drugs for NASH.

Methods

BMDMs and THP1 cells were used to construct an inflammasome activation model, and then we evaluated the effect of epalrestat on the NLRP3 inflammasome activation. Western blot, real-time qPCR, flow cytometry, and ELISA were used to e

SUBMITTER: Shi W 

PROVIDER: S-EPMC10560438 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature